ReviewNatural products and bioprospecting2018
Small-Molecule Targets in Tumor Immunotherapy.
Review in Natural products and bioprospecting, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy.Biomolecules · 2025Review
- A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1.RSC medicinal chemistry · 2024Article
- The cGAS-STING pathway in COPD: targeting its role and therapeutic potential.Respiratory research · 2024Review
- Design, Synthesis, and Evaluation of 8-(ACS medicinal chemistry letters · 2024Article
- cGAS-STING signaling in cardiovascular diseases.Frontiers in immunology · 2024Review
- Expression analysis of inhibitory B7 family members in Alzheimer's disease.Metabolic brain disease · 2023Article
- NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING Signaling.Cancer research · 2023Article
- Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.International journal of molecular sciences · 2023Article
- Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review).International journal of oncology · 2023Review
- Nanomedicine in Lung Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Antitumor Potential of Immunomodulatory Natural Products.Marine drugs · 2022Review
- A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity.Cancers · 2022Article
- The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.Acta pharmaceutica Sinica. B · 2022Review
- The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.International journal of molecular sciences · 2021Review
- Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy.Oncogene · 2021Review
- A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.Frontiers in immunology · 2021Article
- Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.Genome medicine · 2020Article
- Review
- Controlled Drug Delivery Systems for Oral Cancer Treatment-Current Status and Future Perspectives.Pharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where small-molecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.